Last reviewed · How we verify
Lebrikizumab Pen
Lebrikizumab is a monoclonal antibody that blocks interleukin-4 receptor alpha (IL-4Rα), inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammation.
Lebrikizumab is a monoclonal antibody that blocks interleukin-4 receptor alpha (IL-4Rα), inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammation. Used for Moderate-to-severe atopic dermatitis, Uncontrolled asthma with type 2 inflammation.
At a glance
| Generic name | Lebrikizumab Pen |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | IL-4 receptor antagonist; monoclonal antibody |
| Target | IL-4Rα (Interleukin-4 receptor alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology; Respiratory/Allergy |
| Phase | Phase 3 |
Mechanism of action
IL-4 and IL-13 are key cytokines driving type 2 inflammatory responses. By binding to IL-4Rα, lebrikizumab prevents both IL-4 and IL-13 from activating their downstream signaling pathways, thereby suppressing eosinophilic and allergic inflammation. This mechanism is particularly relevant in diseases characterized by elevated type 2 immune responses.
Approved indications
- Moderate-to-severe atopic dermatitis
- Uncontrolled asthma with type 2 inflammation
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lebrikizumab Pen CI brief — competitive landscape report
- Lebrikizumab Pen updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI